Results 61 to 70 of about 54,372 (282)

Combination Therapy in Participants With Active Psoriatic Arthritis Using Subcutaneous Guselkumab and Golimumab: Week 24 Results From a Phase 2a, Multicenter, Randomized, Double‐Blind, Proof‐of‐Concept Study

Arthritis &Rheumatology, EarlyView.
Objective To assess guselkumab + golimumab combination therapy versus guselkumab monotherapy in participants with active psoriatic arthritis (PsA) and inadequate response to tumor necrosis factor inhibitors (TNFi‐IR). Methods Adults with active TNFi‐IR PsA (three or more tender/swollen joints) were randomized (2:1) to subcutaneous guselkumab (100 mg) +
Jose U. Scher, Iain B. McInnes, Enrique R. Soriano, Joseph F. Merola, Paul Bird, Vinod Chandran, Edaire Cheng, Elena Reynoso, Warner Chen, Maoji Li, Lianne S. Gensler, Philip J. Mease, Christopher T. Ritchlin   +12 more
wiley   +1 more source

From Interferon Signature to the Clinical Landscape: Type I Interferonopathies

Arthritis &Rheumatology, Accepted Article.
Background Type I interferonopathies are heterogeneous diseases driven by dysregulated IFN‐I signaling. Diagnosis is challenging due to clinical/molecular variability and the need for IFN‐I quantification. Objective To characterize the clinical, immunological, genetic, molecular profiles of patients with suspected enhanced IFN‐I signaling, and assess ...
Ismail Yaz, Seza Ozen, Hacer N. Bildik, Canberk Ipsir, Dilara Unal, Saliha Esenboga, Begum Cicek, Mehmet E. Seker, Fatima Aerts‐Kaya, Seher Sener, Mehmet O. Erkan, Hanife Avci, Deniz Cagdas, Ilhan Tezcan   +13 more
wiley   +1 more source

Defining criteria for disease activity states in systemic juvenile idiopathic arthritis based on the systemic Juvenile Arthritis Disease Activity Score [PDF]

Objective To develop and validate cutoff values in the systemic Juvenile Arthritis Disease Activity Score 10 (sJADAS10) that distinguish the states of inactive disease (ID), minimal disease activity (MiDA), moderate disease activity (MoDA), and high ...
Robasto, Francesca, Silva, Rodrigo M., Shalaby, Radwa H., Consolaro, A., Marrani, Edoardo, Villarreal, Giselle, Lotfy, Hala M., Ozen, S., Costi, Stefania, Kriulin, Ivan, Sztajnbok, Flavio, Al‐Mayouf, Sulaiman M., Abu-Zaid, M., Abu‐Rumeleih, S., Hassan, Waleed, Maggio, Maria C., Minoia, F., Civino, Adele, Montin, Davide, Tarantola, Letizia, Khubchandani, Raju, Fouad, Nermeen A., Osman, Naglaa S., Vilaiyuk, Soamarat, Filocamo, Giovanni, Pal, P., Maldar, Naziya P., Almaaitah, Hiba, Al‐Sofyani, Fuad, Bracaglia, C., El Owaidy, R., El Miedany, Yasser, Alzyoud, Raed, Pardeo, M., Khan, A., Mahgoub, Marwa Y., Patrone, Elisa, Bathia, Jigna N., Saad‐Magalhães, Claudia, Eissa, M., Lerkvaleekul, Butsabong, Simonini, Gabriele, De Benedetti, F., Katsicas, María M., Ravelli, A., Rebollo‐Gimenez, Ana I., Mosa, D., Bayindir, Yagmur, Licciardi, F., Abu‐Shady, Hend, Vyzhga, Y., Radwan, Ahmed R., Alexeeva, Ekaterina, Dvoryakovskaya, Tatyana, Marino, Achille, Nasef, S., Kostik, M., Dāvidsone, Zane, Pistorio, Angela, Adel, Yasmin, Diomeda, Federico, Alsuweiti, Motasem, Rosina, Silvia, Tabra, Samar A. A., Rossano, Martina, El‐Ghoneimy, Dalia H., Mohamed, Sheren E. M., Belozerov, Konstantin E.   +67 more
core   +1 more source

Age‐related differences in hydroxychloroquine‐associated adverse events: A pharmacovigilance study based on the FDA Adverse Event Reporting System

British Journal of Clinical Pharmacology, EarlyView.
Aims This real‐world pharmacovigilance study utilizes FDA Adverse Event Reporting System (FAERS) data (2004–2024) to characterize age‐related disparities in hydroxychloroquine (HCQ)‐associated adverse events (AEs), addressing gaps in age‐stratified risk assessment. Methods Disproportionality analysis (reporting odds ratios, RORs) and parametric Weibull
Guanghan Sun, Jingrong Yang, Lei Wan, Xia Xu, Jing Wang   +4 more
wiley   +1 more source

Burden of childhood-onset arthritis

Pediatric Rheumatology Online Journal, 2010
Juvenile arthritis comprises a variety of chronic inflammatory diseases causing erosive arthritis in children, often progressing to disability. These children experience functional impairment due to joint and back pain, heel pain, swelling of joints and ...
Hassett Afton L, Peterson Margaret GE, Moorthy Lakshmi N, Lehman Thomas JA   +3 more
doaj   +1 more source

Inflammation Unchecked: Concurrent Kawasaki Disease and Stevens‐Johnson Syndrome in an 18‐Month‐Old Child

Arthritis Care &Research, EarlyView.
Catherine Deffendall, Jodi Backalar, Elizabeth Acevedo Zapata, Adriana Della Porta, Lorin Bibb, Tyler Reese, Charlotte M. Brown   +6 more
wiley   +1 more source

Ten‐Year Public Expenditure Savings Associated with TNF Inhibitor Biosimilars under Australia's Pharmaceutical Benefits Scheme

Clinical Pharmacology &Therapeutics, EarlyView.
Biologic therapies are a major and growing driver of pharmaceutical expenditure globally, with tumor necrosis factor (TNF) inhibitors among the most widely used and costly biologics. In Australia, these therapies are funded through the Pharmaceutical Benefits Scheme (PBS), where biosimilars offer lower cost alternatives; however, the long‐term public ...
Chin Hang Yiu, Bella D. Ianni, Richard O. Day, Jacques Raubenheimer, Christine Y. Lu   +4 more
wiley   +1 more source

Juvenile idiopathic arthritis in two tertiary centres in the Western Cape, South Africa

, 2011
Juvenile idiopathic arthritis (JIA) is defined as arthritis of unknown aetiology that begins before the 16th birthday and persists for at least 6 weeks, other conditions being excluded.
Weakley, Kate
core  

Skin Manifestations of Rheumatoid Arthritis, Juvenile Idiopathic Arthritis, and Spondyloarthritides.

, 2017
Extra-articular manifestations of rheumatoid arthritis, juvenile idiopathic arthritis, and various spondyloarthritides including psoriatic arthritis, ankylosing spondylitis, reactive arthritis, and inflammatory bowel disease-associated spondyloarthritis ...
Nikhil Yawalkar, Chua-Aguilera, Carolyn Jean, Burkhard Möller, Carolyn Jean Chua-Aguilera, Yawalkar, Nikhil, Möller, Burkhard   +5 more
core   +1 more source

Piezosurgical partial ostectomy of the incisive bone for an ossifying fibroma removal in a 4‐year‐old Warmblood gelding

Equine Veterinary Journal, EarlyView.
Abstract Background Ossifying fibromas are uncommon in horses and complete surgical excision with premaxillectomy, maxillectomy or mandibulectomy is recommended. Piezosurgery has been previously used in equines only in one study. Objective To report a case of ossifying fibroma treated with piezosurgery and to describe its follow‐up.
G. Forni, M. E. Falomo, I. Casalini, M. Isola   +3 more
wiley   +1 more source